Enanta Pharmaceuticals Inc (ENTA NASDAQ) stock market data APIs
$13.6521
0.02(0.1%)
as of March 6, 2026
Try our APIs with
free plan!
Enanta Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Prev. Close
13.6521
Open
13.6721
High
14.0665
Low
13.2662
52 wk Range
4.09-17.15
Market Cap
399 M
Shares Outstanding
29 019 K
Revenue
66 980 K
EPS
-0.42
Beta
0.972
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Enanta Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enanta Pharmaceuticals Inc data using free add-ons & libraries
Get Enanta Pharmaceuticals Inc Fundamental Data
Enanta Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 66 980 K
- EBITDA: -68 132 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-09
- EPS/Forecast: -0.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enanta Pharmaceuticals Inc News
New
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $1.05 per share a year ago. These fig...
Stocks Set for Muted Open as Bond Yields Climb, Key U.S. Economic Data Awaited
March S&P 500 E-Mini futures (ESH26) are down -0.03%, andMarch Nasdaq 100 E-Mini futures (NQH26) are down -0.19% this morning, pointing to a muted open on Wall Street as rising Treasury yields curbed ...
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in Developmen...
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., January 05, 2026--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on ...
Get Enanta Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
